Methocarbamol Marketing

Methocarbamol is a central muscle relaxant used to treat skeletal muscle spasms. The trademark is called Robaxin. The mechanism of action of methylaminomethane is currently unclear, but may involve inhibition of carbonic anhydrase. The muscle relaxation of Methocarbamol is mainly attributed to central inhibition; However, Methocarbamol has also been reported to prolong the peripheral effects of muscle refractory period.
In 2016, it was the 187th largest prescription drug in the US with more than 3 million prescription drugs.
Methocarbamol, which contains no other ingredients, is marketed under the Robaxin brand in the United Kingdom, the United States and Canada; it is marketed in Lumirelax in France, Ortoton in Germany, and sold under many other names worldwide. In combination with other active ingredients, sold under other names: acetaminophen (paracetamol) under the trade names Robaxacet and Tylenol Body Pain Night; ibuprofen as Robax Platinum; acetylsalicylic acid in the United States and Canada as Robaxisal. However, in Spain, the trade name Robaxisal is used in the paracetamol combination rather than the Robaxacet. These combinations are also available under the generic name from an independent manufacturer.